Plain-English translation of NCT06355739 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing three versions of a new treatment called BIC-19GG, BIC-2019, and BIC-2219 for children with a type of blood cancer called B-cell acute lymphoblastic leukemia that has either not responded to chemotherapy or has returned after treatment. The medication works by taking your child's own immune cells, training them in the laboratory to recognize and fight cancer cells, and then putting them back into the body. This approach is designed to help children whose cancer is resistant to standard treatments.
For children whose leukemia comes back or doesn't respond to chemotherapy, treatment options are limited and outcomes are often poor. This medication offers a different approach by using the body's own immune system to fight the cancer, which may help children who have exhausted other options.
You likely qualify if…
You likely don't qualify if…
Your child would receive the new treatment through a medical infusion (like a blood transfusion). The trial will monitor your child closely to see how well the treatment works and watch for any side effects. You will need to visit the hospital or clinic for check-ups and tests, with the frequency depending on your child's condition and response to treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China